Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis May 12, 2021 No Comments
GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis May 11, 2021 No Comments
Aslan Pharmaceuticals presents phase I data for the IL13RA1 inhibitor ASLAN-004 May 7, 2021 No Comments
Promising safety data from first dose cohort of phase I study evaluating DSG3-CAART May 4, 2021 No Comments
FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis May 3, 2021 No Comments
RSS